Mechanism of Action of ABIVAX’s First-in-class Anti-HIV Drug Published

News   Apr 15, 2015

 
Mechanism of Action of ABIVAX’s First-in-class Anti-HIV Drug Published
 
 
 

RELATED ARTICLES

PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug Discovery

News

Investment to fund expansion of operations and progression of drug target pipeline.

READ MORE

No Country for Old Genes

News

Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.

READ MORE

CRISPR Editing Stops HIV Virus in Infected Cells

News

Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE